MedTrace Logo

Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial

NCT00378196 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2012-11-14

No results posted yet for this study

Summary

This research is being done to look at the effects of an experimental drug, ranibizumab, for the treatment of a condition called "idiopathic parafoveal telangiectasia" or IPT. IPT is caused by swelling in the retina (the light sensitive tissue in the back of the eye) due to leaky blood vessels in this area. Swelling in the retina can lead to blurry vision.

Conditions

  • Telangiectasia

Interventions

DRUG

Ranibizumab

0.3 mg/0.05 ml dose

DRUG

Ranibizumab

0.5 mg/0.05 ml dose

Sponsors & Collaborators

Principal Investigators

  • Neil M. Bressler, MD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2007-09-30
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00378196 on ClinicalTrials.gov